PT1112083E - Uso de um factor angiogenico para o tratamento de angiopatias microvasculares - Google Patents

Uso de um factor angiogenico para o tratamento de angiopatias microvasculares

Info

Publication number
PT1112083E
PT1112083E PT99946776T PT99946776T PT1112083E PT 1112083 E PT1112083 E PT 1112083E PT 99946776 T PT99946776 T PT 99946776T PT 99946776 T PT99946776 T PT 99946776T PT 1112083 E PT1112083 E PT 1112083E
Authority
PT
Portugal
Prior art keywords
treatment
angiogenic factor
angiopathies
microvascular
microvascular angiopathies
Prior art date
Application number
PT99946776T
Other languages
English (en)
Inventor
George F Schreiner
Richard J Johnson
Original Assignee
Scios Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc, Univ Washington filed Critical Scios Inc
Publication of PT1112083E publication Critical patent/PT1112083E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99946776T 1998-09-09 1999-09-09 Uso de um factor angiogenico para o tratamento de angiopatias microvasculares PT1112083E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27

Publications (1)

Publication Number Publication Date
PT1112083E true PT1112083E (pt) 2004-03-31

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
PT99946776T PT1112083E (pt) 1998-09-09 1999-09-09 Uso de um factor angiogenico para o tratamento de angiopatias microvasculares
PT99968631T PT1109571E (pt) 1998-09-09 1999-09-09 Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT99968631T PT1109571E (pt) 1998-09-09 1999-09-09 Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos

Country Status (13)

Country Link
US (3) US6352975B1 (pt)
EP (2) EP1109571B1 (pt)
JP (2) JP2002532382A (pt)
AT (2) ATE260675T1 (pt)
AU (2) AU6028599A (pt)
BR (2) BR9913564A (pt)
CA (2) CA2340320C (pt)
DE (2) DE69915310T2 (pt)
DK (2) DK1109571T3 (pt)
ES (2) ES2216630T3 (pt)
IL (2) IL141686A0 (pt)
PT (2) PT1112083E (pt)
WO (2) WO2000013703A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109571B1 (en) * 1998-09-09 2004-03-03 Scios Inc. Methods of treating salt-dependent hypertension
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
AU782158B2 (en) * 1999-11-02 2005-07-07 Genentech Inc. Modulation of eNOS activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1414964B1 (en) 2001-08-01 2010-03-24 University Of Bristol Vegf isoform
WO2003015605A2 (en) * 2001-08-20 2003-02-27 University Of Virginia Patent Foundation Use of s-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
WO2006110813A2 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP5158779B2 (ja) * 2005-08-31 2013-03-06 国立大学法人 香川大学 Ｄ−アロースを有効成分とする血圧上昇抑制剤
KR101761424B1 (ko) 2008-12-04 2017-07-26 큐알엔에이, 인크. Ｖｅｇｆ에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(ｖｅｇｆ) 관련된 질환의 치료
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
US11229682B2 (en) 2017-03-30 2022-01-25 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ATE152626T1 (de) 1989-03-24 1997-05-15 Univ California Endothelialer zellwachsfaktor, isolierung und expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
JP2001503755A (ja) * 1996-11-01 2001-03-21 ユーロジーン・リミテッド Ｎｏまたはプロスタサイクリン産生を刺激する薬剤の治療的使用およびデリバリー装置
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
EP1109571B1 (en) * 1998-09-09 2004-03-03 Scios Inc. Methods of treating salt-dependent hypertension

Also Published As

Publication number Publication date
BR9913533A (pt) 2001-06-05
IL141686A0 (en) 2002-03-10
DK1112083T3 (da) 2004-03-08
JP2002532382A (ja) 2002-10-02
CA2340320A1 (en) 2000-03-16
EP1109571B1 (en) 2004-03-03
IL141687A0 (en) 2002-03-10
WO2000013703A3 (en) 2000-07-06
AU6028599A (en) 2000-03-27
WO2000013702A9 (en) 2000-10-19
DE69915310T2 (de) 2005-03-10
EP1112083A2 (en) 2001-07-04
PT1109571E (pt) 2004-05-31
DE69912815T2 (de) 2004-10-21
US20020193288A1 (en) 2002-12-19
US6352975B1 (en) 2002-03-05
WO2000013703A9 (en) 2000-06-02
ATE260675T1 (de) 2004-03-15
ES2216630T3 (es) 2004-10-16
US20040224885A1 (en) 2004-11-11
DE69915310D1 (de) 2004-04-08
DE69912815D1 (de) 2003-12-18
AU5910599A (en) 2000-03-27
CA2340728A1 (en) 2000-03-16
DK1109571T3 (da) 2004-06-21
CA2340320C (en) 2006-11-14
CA2340728C (en) 2007-11-27
EP1112083B1 (en) 2003-11-12
WO2000013702A3 (en) 2000-09-08
WO2000013703A2 (en) 2000-03-16
JP2002524421A (ja) 2002-08-06
ATE253934T1 (de) 2003-11-15
WO2000013702A2 (en) 2000-03-16
ES2211165T3 (es) 2004-07-01
EP1109571A2 (en) 2001-06-27
BR9913564A (pt) 2001-05-22

Similar Documents

Publication Publication Date Title
PT1112083E (pt) Uso de um factor angiogenico para o tratamento de angiopatias microvasculares
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
BR9707819A (pt) Imunogenos peptidicos
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
DK0914116T3 (da) Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DK0967987T3 (da) Sammensætning til behandling af tumorer indeholdende hajbruskekstrakter og anitneoplastiske stoffer
TR199901104T2 (xx) Farmas�tik bile�ikler.
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
DK1303294T3 (da) Fremgangsmåde til behandling af instabil angina pectoris
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein
EP1829535A3 (en) Tissue factor antagonists and methods of use thereof
UA32314A (uk) Спосіб лікування некротичного панкреатиту